Minneapolis, MN—January 30, 2017—Judge Brian R. Martinotti of the District of New Jersey entered an order on Jan. 24 appointing Robins Kaplan LLP® associate Holly Dolejsi to the Plaintiffs’ Steering Committee for the Invokana multidistrict litigation.
Consolidated by the Judicial Panel on Multidistrict Litigation in December 2016, the Invokana cases involve claims that Invokana, a drug used to treat Type 2 diabetes, has been linked to diabetic ketoacidosis, a serious condition characterized by high levels of acid in the blood. Untreated, it can lead to coma or death. Symptoms that may indicate the onset of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing. Ketoacidosis may be present, even if a patient’s blood glucose levels are not very high.
What is Invokana?
Invokana is in a class of drugs called sodium-glucose cotransporter-2 inhibitors, which are used to treat Type 2 diabetes. In December 2015, the U.S. Food and Drug Administration required the makers of Invokana and other SGLT2 inhibitors to warn of the risk of ketoacidosis on their labels. The FDA’s review of reports of adverse events of ketoacidosis associated with the drugs noted that all patients required hospitalization or emergency treatment. To date, more than 100 Invokana cases are pending in the MDL, with more expected to be filed in the coming months.
Learn more about Invokana
If you or someone you know have developed diabetic ketoacidosis while taking Invokana, you may have an Invokana claim.
At Robins Kaplan LLP, we investigate potential claims on behalf of Invokana patients to see if they may have an Invokana case. Our firm includes attorneys experienced in pharmaceutical lawsuits like Invokana. We are careful listeners and your story is important to us. Our on-staff medical advisors are available to answer your questions and listen to your concerns as you determine what to do next.
For a free case evaluation, please call 1.800.553.9910 (toll-free). Our legal nurse consultants are standing by.
